Skip to main content

Table 1 Demographic data of seventy post-bariatric surgery patients; overall and according to weight loss status

From: Skin manifestations after bariatric surgery

 

Total patients (N = 70)

Non-successful weight loss patients (N = 24, 34.3%)

Successful weight loss patients (N = 46, 65.7%)

Mean age (SD)

41 (9.6)

40 (8.7)

42 (10)

Sex

 Male (%)

24 (34.3%)

11 (45.8%)

13 (28.3%)

 Female (%)

46 (65.7%)

13 (54.2%)

33 (71.7%)

Bariatric surgery

 RYGBa

48 (68.6%)

17 (70.8%)

31 (67.4%)

 SGa

22 (31.4%)

7 (29.2%)

15 (32.6%)

Mean (SD) months after surgery

14.5 (20)

9.98 (14.8)

18 (20.8)

Mean (SD) preoperative weight

131.38 (29.85)

137.22 (28.82)

128.33 (30.24)

Mean (SD) preoperative BMI

43.38 (9.68)

50.17 (9.54)

47.44 (9.73)

Mean (SD) current weight

94.83 (23.9)

114.7 (24.88)

84.47 (15.46)

Mean (SD) current BMIa

34.9 (8.14)

42 (8.43)

31.3 (5.03)

Mean (SD) total weight reduction percentage

27.31 (27.37)

16.2 (6.95)

33.11 (7.81)

Mean (SD) EBWLa percentage

60.7 (26.2)

32.9 (13)

75.2 (18.4)

Diet modification

 Yes (%)

59 (84.3%)

21 (87.5%)

38 (82.6%)

 No (%)

11 (15.7%)

3 (12.5%)

8 (17.4%)

Underlying diseases

 Hypertension, n (%)

42 (60%)

15 (62.5%)

27 (58.7%)

 Dyslipidemia, n (%)

38 (54.3%)

16 (66.7%)

22 (47.8%)

 Diabetes, n (%)

37 (52.9%)

15 (62.5%)

22 (47.8%)

 PCOSa, n (%)

19 (27.1%)

5 (20.8%)

14 (30.4%)

 Othersb, n (%)

100 (142.9%)

37 (154.7%)

74 (158.7%)

  1. aBMI body mass index, EBWL percentage excess body weight loss percentage, calculated by [(pre-operative BMI – follow-up BMI)/ (pre-operative BMI – Ideal Body Weight (IBW))] × 100. Ideal body weight was based on a BMI of 25 kg/m2, RYGB Roux-en-Y gastric bypass, PCOS polycystic ovarian syndrome, SG sleeve gastrectomy; (kg/m2)
  2. bOthers underlying diseases are referred to coronary artery diseases, obstructive sleep apnea (OSA), non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD), kidney disease, inflammatory diseases, hypothyroidism, malignancy, hyperuricemia